Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Understanding Local TReatment Patterns and Outcomes With upAdacitinib in IBD Patients in Belgium
- Ulcerative Colitis
- Crohn's Disease
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- AbbVie
- Enrolment target
- 280
- Started
- 27 September 2024
- Main results due
- September 2029
- Study sites
- 11
- Registry updated
- 23 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Participants with a diagnosis of moderate to severe Crohn's disease or Ulcerative colitis, initiated with upadacitinib at least 12 months prior to inclusion, including participants that were initiated on upadacitinib, but later (i.e. at the moment of data collection) discontinued, or switched to another treatment. * Participants initiating commercially available upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study * Participants prescribed upadacitinib in accordance with the approved local label and treatment recommendations Exclusion Criteria: * Participants previously exposed to upadacitinib in a clinical trial or early access program * Participants participating in interventional research (not including non-interventional * Participants with stoma
What this study is about
In the sponsor’s own words, from the registry.
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. This study will assess the (long-term) effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis (UC) and crohn's disease (CD).
Upadacitinib is an approved drug for treating ulcerative colitis (UC) and Crohn's disease (CD). Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Study sites(11)
Imelda Ziekenhuis /ID# 268631
Bonheiden, Antwerpen, Belgium
Recruiting
Universite Libre de Bruxelles - Hopital Erasme /ID# 268632
Anderlecht, Brussels Capital, Belgium
Recruiting
Chu De Charleroi - Hopital Civil Marie Curie /ID# 284063
Lodelinsart, Hainaut, Belgium
Recruiting
Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 284064
Tournai, Hainaut, Belgium
Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 268662
Liège, Liege, Belgium
Recruiting
Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 283334
Genk, Limburg, Belgium
Recruiting
UZ Gent /ID# 268630
Ghent, Oost-Vlaanderen, Belgium
Recruiting
Vitaz /Id# 268637
Sint-Niklaas, Oost-Vlaanderen, Belgium
Recruiting
AZ Groeninge /ID# 268638
Kortrijk, West-Vlaanderen, Belgium
Recruiting
AZ-Delta. /ID# 283323
Roeselare, West-Vlaanderen, Belgium
Recruiting
CHU de Liege /ID# 267209
Liège, Belgium
Recruiting
Showing 11 of 11 sites. 11 of the 11 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06581042. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me